Tenax Therapeutics (NASDAQ:TENX) Posts Quarterly Earnings Results, Beats Estimates By $0.34 EPS

Tenax Therapeutics (NASDAQ:TENX) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.34, Zacks reports.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $6.26 on Wednesday. The company has a 50 day moving average of $6.44 and a 200 day moving average of $5.39. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. StockNews.com assumed coverage on Tenax Therapeutics in a research report on Friday, March 21st. They set a “sell” rating for the company. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.